{"Title":"Sol-Gel Technologies","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"47","Founded":"","Address":"","Phone":"+972-8-931-3433","Web_address":"http://www.sol-gel.com.","Market_cup":"$215.8mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-31.0 mil (last 12 months)","Symbol":"SLGL","Exchange":"NASDAQ","Shares":"6.3","Price_range":"$12.00 - $12.00","Est_volume":"$75.0 mil","Manager":"​Jefferies/ BMO Capital Markets​","CO_managers":"JMP Securities/ Raymond James​","Exp_to_trade":"2/1/2018","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications."}